Praised for its ‘deep understanding of the industry’s specific challenges and regulatory landscape’, Baker McKenzie’s life sciences practice is engaged by clients for its capabilities across regulatory, transactional, IP, public law, and compliance matters. Phelim O’Doherty, who leads the ‘commit[ted]’ team, and Jane Hobson both have a track record of handling intricate cross-border transactions for clients ranging from small biotech firms to multinational pharma companies. Julia Gillert is particularly well-placed to advise on regulatory strategies and compliance requirements, while Alexander Gee, who was promoted to partner in June 2025, handles transactions and corporate matters. Jaspreet Takhar is adept at advising on issues at the cutting edge of digital health and regulation. Hiroshi Sheraton and Joanna Ludlam are no longer at the firm.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- 'The firm's healthcare and life sciences practice is unique due to its deep understanding of the industry’s specific challenges and regulatory landscape. I appreciate the team's practical mindset combined with a strong business acumen, which allows them to provide actionable solutions tailored to the fast-paced healthcare environment.'
- 'The lawyers at this firm are highly responsive and client-focused, making a significant impact on our collaboration. The entire team consistently goes above and beyond to ensure we receive timely insights and tailored solutions, particularly in urgent situations. This commitment to understanding our unique challenges and providing fast, effective responses is something we greatly value.'
Key clients
- AbbVie
- Astellas Pharma Inc.
- Baxter
- Biogen
- Clayton, Dubilier & Rice, LLC (CD&R)
- Donaldson
- eMed
- Galapagos NV
- GSK
- Haleon
- Johnson & Johnson
- Lyra Health
Work highlights
Advised Haleon on the divestment of its global (excluding US) nicotine replacement therapy business related to the Nicabate, Nicotinell, Thrive and Habitrol brands.
Advised on Project Nova, a transaction for Galapagos N.V. involving its proposed separation into two entities: a new company (SpinCo), which will be focused on building a pipeline of innovative medicines through transactions, and Galapagos, which would continue to advance its global cell therapy business.
Advised global private equity firm CD&R on the acquisition of a majority stake in Opella Healthcare, the consumer healthcare division of Sanofi, a French multinational pharmaceutical and healthcare company.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Leading associates
Leading associates with regular involvement in their team's key work, and recognition from peers or clients as being ones to watch.
Practice head
Phelim O’Doherty
Other key lawyers
Jane Hobson; Julia Gillert; Alexander Gee; Jaspreet Takhar; Patrick Edwards; Elina Angeloudi